-- バイオエイジ・ラボ（BIOA）は火曜日、肥満患者を対象とした第1相臨床試験において、開発中の薬剤BGE-102が炎症性バイオマーカーの「クラス最高の減少効果」を示したと発表した。 同社によると、1日60mgおよび120mgのいずれの投与量でも、高感度C反応性タンパク質（hs-CRP）レベルを少なくとも85%低下させ、良好な安全性プロファイルを維持したという。 同社は上半期中に心血管リスクに焦点を当てた第2相臨床試験を開始し、年内に初期データが得られる見込みだ。 また、バイオエイジは2026年半ばに、糖尿病性黄斑浮腫に対する網膜疾患への治療効果を評価するため、別途概念実証試験を開始する予定だ。 同社の株価は火曜日のプレマーケット取引で9%上昇した。
Price: $20.49, Change: $+1.69, Percent Change: +8.99%
Brazilian Rare Earths (ASX:BRE) said that the mineral resource estimate and scoping study for the Rocha da Rocha critical minerals province are both targeted for mid-2026, according to a Monday Australian bourse filing.Sensor-based ore sorting testing validated a simple, dry beneficiation pathway for the Monte Alto project, while a metallurgical optimization program validated low-temperature acid-cure processing at 150 degrees celsius, with a 15 kilograms blended composite scale-up test confirming high extraction performance and strong scalability, the filing said.The company expects to submit an economic development plan for the project to Brazil's National Mining Agency in the June quarter.Brazilian Rare Earths' shares rose nearly 4% in recent trading on Monday.
CITIC Securities (HKG:6030, SHA:600030) posted net profit attributable to owners of 10.2 billion yuan for the first quarter of 2026, up 55% from 6.61 billion yuan a year earlier, according to an April 24 Hong Kong bourse filing.Hong Kong-listed shares of the firm were up nearly 2% in Monday morning trade.Earnings per share came in at 0.67 yuan, compared with 0.43 yuan in the prior-year period.Operating revenue rose 41% to 23.2 billion yuan from 16.4 billion yuan.
Zhejiang NHU's (SHE:002001) net profit attributable to shareholders in the first quarter rose 15% to 6.76 billion yuan from 5.87 billion yuan a year earlier, according to a Saturday filing on the Shenzhen bourse.Earnings per share climbed 16% year on year to 2.21 yuan from 1.91 yuan.Operating revenue increased 3% to 22.3 billion yuan from 21.6 billion yuan in the prior year.